De­fense De­part­ment en­lists Evotec to make new an­ti­body treat­ments for Mpox and oth­er pox­es

The De­part­ment of De­fense will pay up to $74 mil­lion to Evotec’s Seat­tle-based sub­sidiary to de­vel­op new an­ti­body treat­ments for or­thopoxvirus­es — a cat­e­go­ry of pathogens …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER